




To the Editor: Human mono-
cytic ehrlichiosis is a tick-borne in-
fectious disease caused by Ehrlichia 
chaffeensis (1). Serologic studies have 
indicated  E. chaffeensis infection in 
Latin American countries: Venezuela 
(2), Mexico (3), Argentina (4), Chile 
(5), and Brazil (6). However, no mo-
lecular evidence for E. chaffeensis has 
been reported.
In December 2001, a 9-year-old 
boy was admitted to a hospital in 
Carabobo, Venezuela, after 3 days 
of fever (39°C–41°C), malaise, an-
orexia, headache, abdominal pain, 
and cutaneous tick-bite lesions. Dur-
ing the 6 weeks before admission, the 
patient had been exposed to ticks in 
a rural area (Cojedes, Venezuela). At 
the time of physical examination, the 
patient appeared acutely ill with fe-
ver (41°C), dehydration, somnolence, 
conjunctivitis, facial edema, cervical 
adenomegaly, soft depressible abdo-
men painful to palpation, and hepa-
tomegaly. Cardiopulmonary exami-
nation found regular cardiac sounds 
with systolic tricuspid murmur and 
abnormal bilateral respiratory sounds 
(rhonchi). Skin examination showed 
multiple tick bites and an erythema-
tous maculopapular rash. Appropriate 
informed consent was obtained.
Blood values were as follows: 
leukocytes 6,280 cells/mm3 (84% 
neutrophils, 13% lymphocytes, 2% 
monocytes, 1% eosinophils), platelets 
130,000/μL, hemoglobin 12.5 g/dL, 
glucose 102 mg/dL, blood urea 28.3 
mg/dL, creatinine 0.9 mg/dL, aspar-
tate aminotransferase (AST) 20.4 U/L, 
alanine aminotransferase (ALT) 54.4 
U/L, erythrocyte sedimentation rate 
(Katz index) 15 mm/h, prothrombin 
time ratio 1.02, partial thromboplastin 
time –2.8 s. Radiographs of the thorax 
showed bilateral inﬁ  ltrate.  Echocar-
diogram showed minor tricuspid in-
sufﬁ  ciency. Serologic tests were nega-
tive for Epstein-Barr and hepatitis B 
and positive for cytomegalovirus and 
hepatitis A viruses. Blood and stool 
cultures were negative. Blood samples 
were taken 4 and 35 days after illness 
onset; buffy-coat smears were stained 
with Dip Quick (Jorgensen Laborato-
ries, Inc., Loveland, CO, USA), and 
immunologic and PCR tests were 
performed. Immunoglobulin (Ig) M 
against dengue virus was present at 
days 4 and 35 of illness; IgG against 
dengue was absent on day 4 and pres-
ent on day 35. PCR and viral isolation 
tests for dengue virus were negative. 
Serologic tests for E. chaffeensis (in-
direct immunoﬂ  uorescence) were also 
negative on day 4 and positive (256) 
on day 35. Detection of Ehrlichia spe-
cies–speciﬁ  c DNA was performed by 
using nested PCR as described (7).
Starting on the ﬁ  rst day of hospi-
talization, the patient was treated with 
doxycycline (14 days) and chloram-
phenicol (8 days). After 24 hours, mal-
aise, headache, facial edema, and con-
junctivitis improved. After 48 hours, 
fever and rash were gone. After 3 days, 
his appetite improved; progressively 
over time, cervical adenomegaly and 
cutaneous lesions improved. Abdomi-
nal pain persisted for 7 days after treat-
ment. Nausea and vomiting started 2 
days after admittance; on day 7, vomit 
was of coffee-ground consistency. All 
remaining symptoms abated thereafter. 
The patient had diarrhea during days 3–
6 after admittance; hepatomegaly dis-
appeared after 4 days. Ultrasonographic 
images of the abdomen indicated acute 
cholecystitis and hepatosplenomegaly; 
endoscopic examination of the upper 
digestive tract showed hyperplasia, hy-
peremia, and linear and pseudomem-
branous lacerations in the middle and 
distal thirds of the esophagus (Mal-
lory-Weiss syndrome) and moderate 
erythema of the stomach. Test results 
for  Helicobacter pylori and Giardia 
lamblia were negative.
Laboratory results showed leu-
kopenia and monocytosis on day 5 of 
illness. Leukocyte count was within 
reference range thereafter; throm-
bocytopenia was present until day 7 
(99,000/mm3). ALT was elevated from 
day 3 and peaked (481 IU) on day 7. 
AST levels increased on day 5 and 
peaked (215 IU) on day 7. Both values 
decreased progressively to reference 
levels (after 25 days for ALT and 46 
days for AST). Lactic dehydrogenase 
was elevated for 9 days while eryth-
rocyte count, sedimentation rate, and 
serum glucose, amylase, urea, creati-
nine, bilirubin, calcium, sodium, and 
potassium remained within reference 
limits. The patient was released after 
8 days of hospitalization.
The buffy-coat smear performed 
4 days after illness onset showed ba-
sophilic intracytoplasmic inclusions 
inside vacuoles of lymphocytes and 
monocytes, with typical features of 
morulae reported for human monocyt-
ic ehrlichiosis (Figure). Nested PCR 
analysis was positive for E. chaffeen-
sis, and sequencing of the ampliﬁ  ed 
DNA fully conﬁ  rmed the 16S rRNA 
targeted sequence.
This report provides molecular ev-
idence of E. chaffeensis infection in a 
patient with acute disease in Venezuela. 
A previous case of human monocytic 
ehrlichiosis in a 17-month-old girl in 
Venezuela has been demonstrated sero-
logically (2). E. canis in an asymptom-
atic patient in Venezuela has been dem-
onstrated by PCR and culture isolation 
(8) and was recently demonstrated in 
symptomatic patients (9). Excluding 
the esophageal lesions (Mallory-Weiss 
syndrome), our case is compatible with 
cases reported previously (10). The 
clinical manifestations of ehrlichiosis 
are similar to those of dengue fever and 
mononucleosis, both common diseases 
in Venezuela. The positive anti-dengue 
IgM and the seroconversion of the IgG 
together with the negative PCR and 
isolation results suggest a recent, inac-
tive infection with dengue virus. 
According to our ﬁ  ndings,  eh-
rlichiosis should be a differential di-
agnosis for febrile patients who have 
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thrombocytopenia, hepatomegaly, and 
recent exposure to ticks. Although 
Amblyomma americanum, the main 
known vector of E. chaffeensis, has 
not been reported in Venezuela, Rhipi-
cephalus sanguineus and A.  cajen-
nense are abundant in rural areas of 
Venezuela; their ability to be vectors 
should be investigated.
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an Inﬂ  uenza 
Pandemic 
To the Editor: Planning for pan-
demic inﬂ  uenza is accepted as an es-
sential healthcare service and has 
included creation of national and in-
ternational antiviral drug stockpiles 
and novel approaches to emergency 
vaccine development (1). The ef-
fectiveness of these strategies in a 
pandemic may be substantial but is 
unknown. More certain is that effec-
tive management of severe and com-
plicated inﬂ  uenza will reduce deaths 
and that demand will exceed available 
treatment resources (2). Appropri-
ate allocation of treatment resources 
is therefore essential, perhaps more 
important than any speciﬁ  c treatment 
such as administering antiviral medi-
cation to symptomatic patients. Re-
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Figure. Peripheral blood smears (buffy-coat preparation) showing variable-sized basophilic 
inclusions (arrows) in mononuclear cells from a 9-year-old boy with human monocytic 
ehrlichiosis, Carabobo, Venezuela. Dip Quick (Jorgensen Laboratories, Inc., Loveland, 
CO, USA) staining; magniﬁ  cation ×1,000.